ricolinostat

Ricolinostat is an orally bioavailable, selective inhibitor of histone deacetylase 6 (HDAC6), developed as a small molecule antineoplastic agent. By selectively binding to and inhibiting HDAC6, ricolinostat disrupts the Hsp90 protein chaperone system through hyperacetylation of Hsp90, preventing aggresomal protein degradation. This leads to accumulation of unfolded and misfolded ubiquitinated proteins in cancer cells, inducing apoptosis and inhibiting tumor growth. Ricolinostat has been investigated primarily for multiple myeloma (especially in combination with proteasome inhibitors), diabetic neuropathies, breast carcinoma, metastatic breast cancer, and lymphoma[1][2][3][4][5][6].

Brand names

ricolinostat

Other names

2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide